Article info
PDFEditorial
Dapagliflozin for type 1 diabetes: ensuring benefits outweigh the risks
- Correspondence to Mr David Erskine, Pharmacy, Guys & St Thomas NHS Foundation Trust, London, UK; david.erskine{at}gstt.nhs.uk
Citation
Dapagliflozin for type 1 diabetes: ensuring benefits outweigh the risks
Publication history
- First published February 26, 2020.
Online issue publication
February 26, 2020
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.